The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led ...
Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental ...
Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...
William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its ...
Vertex may have pivoted away from the space, but candidates in development by Arrowhead/Takeda, Wave, Korro and others could ...
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback